Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

✍ Scribed by Iveson, Timothy; Donehower, Ross C; Davidenko, Irina; Tjulandin, Sergey; Deptala, Andrzej; Harrison, Mark; Nirni, Somanath; Lakshmaiah, Kuntegowdanahalli; Thomas, Anne; Jiang, Yizhou; Zhu, Min; Tang, Rui; Anderson, Abraham; Dubey, Sarita; Oliner, Kelly S; Loh, Elwyn

• Book ID: 125508140
• Publisher: The Lancet
• Year: 2014
• Tongue: English
• Weight: 339 KB
• Volume: 15
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/S1470-2045(14)70023-3